Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. V. Rukavishnikov has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Outbreak of a New Infectious Disease COVID-19: β-coronaviruses as a Threat to Global Healthcare

    by D. V. Gorenkov, L. M. Khantimirova, V. A. Shevtsov, A. V. Rukavishnikov, V. A. Merkulov, Yu. V. Olefir

    Coronaviruses are the largest group of known positive-strand RNA viruses. Coronavirus infection can affect various animal species, as well as humans. Over the past two decades, coronaviruses have caused epidemic outbreaks of two respiratory diseases: the Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome. At the end of 2019, a new type of virus was detected in China. The virus has been spread by humantohuman transmission and has caused a viral pneumonia outbreak. The emergence of a new coronavirus proves that the diseases caused by this group of viruses pose a threat to global health due to the potential for a pandemic, and, therefore, need careful monitoring. The objective of the study was to analyse the current epidemic situation for the new coronavirus infection (COVID-19) caused by SARS-CoV-2, taking into account previous outbreaks of infections caused by MERS-CoV and SARS-CoV β-coronaviruses which pose the greatest threat to human health. The review briefly describes two epidemic outbreaks caused by SARS-CoV (2002–2004) and MERS-CoV (2012–present), summarises the current epidemic situation for the new SARS-CoV-2 coronavirus, describes the main restrictive measures undertaken to prevent the spread of infection in Russia. The paper considers aspects of potential specific therapy and the development of prophylactic vaccines against the new coronavirus infection. The review concludes that SARS-CoV-2 has pandemic potential and that new strains of β-coronaviruses are likely to cause outbreaks in the future. The paper points to the need for careful monitoring of the disease and conducting preventive anti-epidemic measures to curb the spread of infection.


  • Open Access

    Vaccine Safety and Efficacy in Preventing Rotavirus Infection

    by V. A. Shevtsov, E. E. Evreinova, I. N. Indikova, L. M. Khantimirova, D. V. Gorenkov, A. V. Rukavishnikov

    The rotavirus infection causes acute gastroenteritis and is a major cause of lethal severe dehydrating diarrhoea in children under 5 years of age worldwide. Live attenuated rotavirus vaccines are the only means of preventing severe forms of the disease. The aim of the study was to analyse the twenty-year international experience of prophylactic immunisation against rotavirus infection. The paper summarises safety and efficacy data on the long-term use of Rotarix® (Belgium) and RotaTeq® (USA) for the prevention of rotavirus infection in the WHO European Region, the European Union and other countries. It addresses the development of correlates of immune protection for vaccines as well as evaluation of efficacy and safety of the new vaccines Rotavac® and Rotasiil® (India) in clinical trials. The authors analysed international experience of using the vaccines in countries that do not keep records of infant mortality from diarrhoea. The study summarises the results of clinical studies on the use of new vaccines prequalified by WHO in 2018 in regions with high rates of infant mortality from diarrhoea. It was demonstrated that vaccination not only reduces the rates of hospital admission of immunised children, but also contributes to the development of herd immunity. Rotarix® and RotaTeq® vaccines are authorised or included in the national immunisation schedules of many countries, but this type of vaccination is not mandatory in most of these countries. Vaccination coverage in the EU countries is about 24 %. Alternative vaccination schemes using live attenuated vaccines based on strains derived from newborn children, and parenteral rotavirus vaccines which do not replicate in the intestine may help reduce existing risks. It was concluded that the introduction of live rotavirus vaccines in immunisation schedules should be accompanied by the analysis of incidence of intussusception of the small intestine before and after the introduction of mass immunisation, and by active pharmacovigilance.


  • Open Access

    Analysis of Measles Incidence in Russia and Problems of Measles Prevention at the Elimination Stage

    by T. N. Yunasova, D. V. Gorenkov, A. V. Rukavishnikov, A. A. Movsesyants, V. A. Merkulov

    The review analyses measles incidence in Russia at the elimination stage. Epidemiological studies have revealed changes in the measles epidemic process in Russia. It was shown that whereas the specificity of the epidemic process in the pre-vaccination period was mainly determined by the influence of the infectious agent, lately the impact of the social factor has increased. There was an increase in the impact of decreed groups on maintaining the circulation of the virus in the Russian Federation. The aim of the study was to analyse the specificity of the measles epidemic process in Russia, to identify the major current problems of measles vaccination, to reveal reasons that prevent measles elimination in the country given the present environment, and to formulate possible ways of solving them. The article demonstrates the role of migration processes within the country and infection importation from neighboring territories in the rise of disease outbreaks. The article discusses Russian regulatory documents that are devoted to combating the spread of measles, their consistent replacement and refinement bearing in mind the changing epidemiological situation and the current WHO criteria and guidelines for the infection elimination. High-level epidemiological surveillance of the infection is a key factor in choosing the optimal strategy of measles vaccination. The article lists indicators of epidemiological surveillance effectiveness. It also highlights the importance of molecular genetic monitoring of the measles pathogen. The authors outline measures that are necessary to achieve measles elimination in the Russian Federation given the current epidemiological situation.


  • Open Access

    Post-approval Variations to Dossiers for Vaccines: Analysis of Regulatory and Methodological Approaches Used in the Russian Federation and Abroad

    by V. A. Shevtsov, Yu. V. Olefir, V. A. Merkulov, V. P. Bondarev, I. N. Indikova, E. E. Evreinova, A. V. Rukavishnikov, L. M. Khantimirova, D. V. Gorenkov

    Внесение изменений в документы регистрационных досье на вакцины: анализ нормативно-методических подходов в Российской Федерации и за рубежом


  • Open Access

    Retrospective Analysis of Viral Hepatitis B Incidence in Russia from 2013 to 2017 in the Context of Preventive Vaccination

    by L. M. Khantimirova, T. Yu. Kozlova, E. L. Postnova, V. A. Shevtsov, A. V. Rukavishnikov

    The article presents the results of a retrospective analysis of viral hepatitis B incidence in the Russian Federation from 2013 to 2017, taking into account the use of vaccines included into the National Immunisation Schedule and the Immunisation Programme in Case of Epidemic Outbreaks. The analysis of the data revealed a trend towards a reduction in the incidence of acute and chronic forms of hepatitis B in the territory of the Russian Federation during the past five years. The reduction of viral hepatitis B incidence was achieved thanks to a higher vaccination coverage of both children and adults. The article presents an overview of monovalent and combination recombinant hepatitis B vaccines licensed in the Russian Federation. It describes the WHO position on preventive vaccination against viral hepatitis B, and pays special attention to vaccination of people at risk. The article considers promising areas for improving immunobiological products for hepatitis B prevention, including new technologies used in vaccine production, development and introduction of new adjuvants or adjuvants systems, and development of therapeutic vaccines.


  • Open Access

    Analysis of Efficacy and Safety of Tick-Borne Encephalitis Vaccines

    by T. Yu. Kozlova, L. M. Khantimirova, A. V. Rukavishnikov, V. A. Shevtsov

    В статье приведен анализ эффективности и безопасности вакцин для профилактики клещевого энцефалита (КЭ), разрешенных для применения на территории Российской Федерации. Показано, что используемые в настоящее время вакцины КЭ отечественного и зарубежного производства обеспечивают высокую иммуногенность, безопасность и эпидемиологическую эффективность в регионах с массовым охватом вакцинацией. Все зарегистрированные вакцины соответствуют основным принципам взаимозаменяемости по показаниям к применению с учетом возрастных ограничений, перечню медицинских противопоказаний, схемам вакцинации, составу вакцин, а также показателям безопасности, иммунологической активности и эффективности. Своевременные меры специфической профилактики приводят к снижению заболеваемости КЭ в эндемичных регионах.